G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
Abhishek Maiti,Courtney D. DiNardo,Caitlin R. Rausch,Jorge E. Cortes,Naveen Pemmaraju,Naval Daver,Farhad Ravandi,Guillermo Garcia-Manero,Gautam Borthakur,Kiran Naqvi,Maro Ohanian,Nicholas J. Short,Yesid Alvarado,Christopher B. Benton,Tapan M. Kadia,Koichi Takahashi,Musa Yilmaz,Nitin Jain,Steven M. Kornblau,Koji Sasaki,Michael Andreeff,Prithviraj Bose,Alessandra Ferrajoli,Ghayas C. Issa,Elias Jabbour,Lucia Masarova,Michael Rytting,Philip A. Thompson,Sa A. Wang,Sergej Konoplev,Zhining Chen,Maitrayee Goswami,Rita Maduike,Julio A Guerrero,Qi Zhang,Antonio Cavazos,Helen Ma,Carol Bivins,Allison Wade,Shadiat L Adewale,Susan Tse,Robin Thomas,Kenneth Vaughan,Sherry Pierce,Jing Ning,Wei Qiao,John S. Welch,Hagop M. Kantarjian,Marina Konopleva +48 more
TL;DR: It is hypothesized that VEN with 10-day decitabine (DEC) may offer superior efficacy in AML, and this high-risk cohort included 52% of pts ≥70 yrs (interquartile range [IQR], 61-74), 54% pts were men, 28% pt had ECOG PS ≥2, and 67% pts had adverse-risk AML.
Journal ArticleDOI
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
TL;DR: A case report of a patient in whom the FIP1L1-PDGFRA was discovered as he evolved from CMML to acute myeloid leukemia (AML) and subsequent therapy with imatinib led to complete remission.
Journal ArticleDOI
Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL).
Farhad Ravandi,Elihu H. Estey,Jorge E. Cortes,Susan O'Brien,Sherry Pierce,Mark Brandt,Alessandra Ferrajoli,Gautam Borthakur,Marina Konopleva,Srdan Verstovsek,Guillermo Garcia-Manero,Stefan Faderl,Hagop M. Kantarjian +12 more
TL;DR: The combination of ATRA and ATO (with or without GO) as initial therapy for APL is highly effective and safe; it can potentially substitute for chemotherapy containing regimens in high and low risk patients.
Journal ArticleDOI
Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.
Nicholas J. Short,Hagop M. Kantarjian,Marina Konopleva,Nitin Jain,Xuelin Huang,Farhad Ravandi,William G. Wierda,Gautam Borthakur,Koji Sasaki,Ghayas C. Issa,Yesid Alvarado,Naveen Pemmaraju,Guillermo Garcia-Manero,Jennifer Thankachan,Rebecca Garris,Elias Jabbour +15 more
TL;DR: Achievement of a complete molecular remission (CMR) is associated with superior outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Journal ArticleDOI
Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial
Musa Yilmaz,Hagop M. Kantarjian,Muharrem Muftuoglu,Tapan M. Kadia,Marina Konopleva,Gautam Borthakur,Courtney D. DiNardo,Naveen Pemmaraju,Nicholas J. Short,Yesid Alvarado,Guillermo Montalban Bravo,Carissa Jurisprudencia,Allison Pike,Maro Ohanian,Elias Jabbour,Guillermo Garcia-Manero,Vivian Ruvolo,Farhad Ravandi,Michael Andreeff,Naval Daver +19 more
TL;DR: CRc criteria were as published in the phase III ADMIRAL and QUANTUM-R studies, and three of 4 CRc pts proceeded to allogeneic stem cell transplantation (ASCT) and are alive post-ASCT and 2 were alive in remission at last f/u.